Ashish Life Science Private Limited

Ashish Life Science Private Limited, established in 1992, is a prominent Indian pharmaceutical exporter specializing in finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company is headquartered in Mumbai, Maharashtra, India, with its registered office located at 213, Laxmi Plaza, Laxmi Industrial Estate, New Link Road, Andheri (W), Mumbai - 400053. As a private, non-government company, it is classified under the Corporate Identification Number (CIN) U24100MH1992PTC064810. The authorized capital stands at ₹53.55 million, with a paid-up capital of ₹47.95 million. Ashish Life Science is part of the Ashish Group of Industries, which has been operational since 1975. The company employs between 200 to 500 professionals, reflecting its substantial presence in the pharmaceutical manufacturing sector.

Ashish Life Science operates a state-of-the-art manufacturing facility located in Tarapur, Maharashtra, India. This plant has received approvals from the World Health Organization Good Manufacturing Practice (WHO GMP), European Union Good Manufacturing Practice (EU GMP), and the Australian Pesticides and Veterinary Medicines Authority (APVMA), underscoring its adherence to international quality standards. The facility is equipped with advanced technology and ergonomic infrastructure, enabling the production of a diverse range of veterinary dosage forms. These include water-soluble powders and granules in sachets and drums ranging from 5g to 25 kg, catering to both small and large-scale farmers, as well as extensive poultry and dairy operations. Additionally, the plant manufactures bolus and tablet formulations for large and small animals, demonstrating excellent bioequivalence properties in ruminants and non-ruminants. Oral liquid and paste formulations are produced in a dedicated unit with a daily capacity of 3,000 liters, offering customization in taste, color, and flavor to meet client specifications. The liquid injectable plant, covering 761 square meters, is equipped with ultra-modern machinery, including a fully automated tunnel with a PLC system, and has a filling capacity of 2,000 liters per day.

The leadership team at Ashish Life Science Private Limited is spearheaded by Managing Director Raujesh Agarrwal, who has been instrumental in steering the company's strategic direction and growth. (craft.co) The company's board of directors includes Rajkumar Harnathrai Agarwal, Prem Venkatachalam Pavoor, Parimal Merchant, Swati Raunak Phadnis, and Bhavik Bhupendra Parekh, each contributing their expertise to the company's operations and strategic initiatives. This diverse leadership team underscores the company's commitment to innovation, quality, and customer satisfaction in the pharmaceutical manufacturing sector.

Ashish Life Science Private Limited has established a significant presence in regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company's manufacturing facility in Tarapur, Maharashtra, has been approved by the European Union Good Manufacturing Practice (EU GMP) and the Australian Pesticides and Veterinary Medicines Authority (APVMA), highlighting its compliance with stringent international standards. These approvals facilitate the company's market access in these regions, enabling it to export a range of veterinary pharmaceutical products. The company's adherence to international quality standards and regulatory requirements positions it favorably in these markets, allowing for the distribution of its products to a broader customer base.

Ashish Life Science Private Limited has expanded its reach into emerging markets across Africa, Latin America, and Southeast Asia. The company's commitment to quality and regulatory compliance has enabled it to establish partnerships and distribution networks in these regions. By obtaining approvals from international health authorities, including the World Health Organization (WHO), the company has facilitated the registration and marketing of its products in various countries. This strategic approach has enhanced the company's global footprint, allowing it to serve a diverse clientele and contribute to the improvement of animal health worldwide.

Ashish Life Science Private Limited demonstrates a diversified geographic strategy by exporting its products to over 60 countries worldwide. This extensive reach mitigates concentration risk and underscores the company's ability to adapt to various market dynamics. The company's strategic direction focuses on expanding its global presence while maintaining high standards of quality and compliance with international regulations. By leveraging its manufacturing capabilities and adhering to stringent quality norms, Ashish Life Science continues to strengthen its position in both established and emerging markets.

As of March 2026, specific details regarding Ashish Life Science Private Limited's interactions with the U.S. Food and Drug Administration (FDA), including facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history, are not publicly available. The company's focus on international markets, particularly in Europe and Australia, suggests that its primary regulatory engagements may be with agencies such as the European Medicines Agency (EMA) and the Australian Therapeutic Goods Administration (TGA). For comprehensive information on FDA-related activities, direct inquiries to the company or the FDA would be advisable.

Ashish Life Science Private Limited's manufacturing facility in Tarapur, Maharashtra, has been approved by the World Health Organization Good Manufacturing Practice (WHO GMP) and the European Union Good Manufacturing Practice (EU GMP). These certifications affirm the company's commitment to maintaining high-quality manufacturing standards and adhering to international regulatory requirements. The EU GMP certification, in particular, facilitates the company's access to European markets, enabling the export of its veterinary pharmaceutical products to a broader customer base.

Ashish Life Science Private Limited holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO), the national regulatory authority in India. The company's facility in Tarapur, Maharashtra, complies with the manufacturing standards set by the CDSCO, ensuring the production of high-quality pharmaceutical products. Additionally, the company has obtained necessary approvals from state drug controllers and export No Objection Certificates (NOCs), facilitating the export of its products to various international markets. These regulatory compliances underscore the company's dedication to quality and adherence to both national and international standards.

As of March 2026, there are no publicly available records indicating any Form 483 observations, warning letters, or import alerts issued to Ashish Life Science Private Limited by regulatory authorities. The company's adherence to international quality standards and regulatory requirements suggests a strong compliance record. For the most current information, it is recommended to consult the official websites of relevant regulatory bodies or contact the company directly.

In the veterinary pharmaceutical sector, Ashish Life Science Private Limited faces competition from both domestic and international companies. While specific market share data is not publicly available, the company's extensive product portfolio and international certifications position it favorably in the market. The company's focus on quality, regulatory compliance, and customer satisfaction differentiates it from competitors, enabling it to establish strong relationships with partners, distributors, and key retailers across more than 60 countries.

Ashish Life Science Private Limited's key differentiators include its adherence to international quality standards, as evidenced by certifications such as WHO GMP and EU GMP. The company's diverse product portfolio, encompassing various veterinary dosage forms, and its ability to customize formulations to meet client specifications further distinguish it in the market. Additionally, the company's global presence and commitment to regulatory compliance enhance its competitive advantage.

Ashish Life Science Private Limited's current strategic direction focuses on expanding its global footprint by exporting a wide range of veterinary pharmaceutical products to over 60 countries. The company's adherence to international quality standards and regulatory requirements positions it favorably in both established and emerging markets. Looking ahead, the company aims to strengthen its market presence by leveraging its manufacturing capabilities and commitment to quality, ensuring continued growth and success in the pharmaceutical manufacturing sector.

Ashish Life Science Private Limited has demonstrated a strong track record in pharmaceutical manufacturing, with a total export value of $483,000 USD and 94 shipments across five products in two therapeutic categories. The company's portfolio concentration is notable, with its top five products accounting for 100% of its exports. This focus on a select range of products indicates a strategic approach to market penetration and product specialization. The company's adherence to international quality standards and regulatory requirements further underscores its reliability as a supplier.